Alexion Pharmaceuticals, Inc. (ALXN)

101.83
0.59 0.58
NASDAQ
Prev Close 101.24
Open 100.79
Day Low/High 100.78 / 102.48
52 Wk Low/High 72.67 / 125.52
Volume 503.36K
Exchange NASDAQ
Shares Outstanding 219.17B
Market Cap 22.33B
P/E Ratio 27.17
Div & Yield N.A. (N.A)
Who's Getting Busy Living?

Who's Getting Busy Living?

These types of companies are winners today.

Alexion downgraded at Goldman

Off the Charts

Off the Charts

Maintain a stock-specific approach until a clearer trend develops.

Off the Charts

Off the Charts

Most investors seem to be in wait-and-see mode due to overall policy confusion.

Off the Charts

Off the Charts

Depending on your risk appetite, it makes sense to keep it light heading into this weekend.

Cramer: Celgene Is a Buy as Biotech Deals Heat-up

Cramer: Celgene Is a Buy as Biotech Deals Heat-up

Jim Cramer looks at the latest biotech deals as Cubist acquires Trius amid changes among Biotech companies.

Cramer: Why Alexion is Ripe for Deal

Cramer: Why Alexion is Ripe for Deal

Jim Cramer looks at the pop in Alexion on rumors of Roche deal, and why this deal makes sense.

Playing the Biotechs

There have been some really good winners this year. By Bob Lang One of the best sectors to play this year has been the biotechs and I would be remiss if I didn't tell you my best play ever was just a couple weeks ago with Onyx Pharmaceutical (ONXX),...

Off the Charts

Off the Charts

We see a lot of short squeezes as money rotates into laggard groups. 

Biotech Makes a Comeback

Biotech Makes a Comeback

Just a natural change in leadership.

Market Takes Aim at Historic Highs Once Again

Market Takes Aim at Historic Highs Once Again

Brittany Umar and Scott Redler, chief strategic officer at T3Live.com, reveal how to trade stocks ahead of earnings season: retail, banks, tech.

Off the Charts

Off the Charts

Upward momentum is lagging.

Mad Money Uncovered: Biomarin and Alexion Orphan Drug Stalwarts

Mad Money Uncovered: Biomarin and Alexion Orphan Drug Stalwarts

Jim Cramer discusses hyper growth names with safety in discussion with Mad Money Research Director Nicole Urken

Two Long Setups in the Pharma Sector

Two Long Setups in the Pharma Sector

Charts of Actavis and Alexion show a combination of positive technical factors.

Alexion downgraded at Lazard

Rules of the Game: Cranking Out the Green

Rules of the Game: Cranking Out the Green

Here's another batch of names with impressive free cash flow, a crucial metric.

Rules of the Game: Further on Free Cash Flow

Rules of the Game: Further on Free Cash Flow

This metric is a prime indicator of financial health, and these health-related stock stand out.

Fitz Bits: Google Primed to Buy

Fitz Bits: Google Primed to Buy

The stock may now be at a tradable low -- but keep your stop tight.

Two Pharma Stocks Enjoying Good Health

Two Pharma Stocks Enjoying Good Health

These large-cap companies have topped expectations for four quarters and are projected to again report robust earnings.

Healthcare Holds Firm

Healthcare Holds Firm

The entire sector did well withstanding Tuesday's decline, but here are a few standouts.

Alexion rated new Neutral at Lazard